Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL; ACCESS Study Group. Opal SM, et al. Among authors: mira jp. JAMA. 2013 Mar 20;309(11):1154-62. doi: 10.1001/jama.2013.2194. JAMA. 2013. PMID: 23512062 Clinical Trial.
The PIRO concept: P is for predisposition.
Angus DC, Burgner D, Wunderink R, Mira JP, Gerlach H, Wiedermann CJ, Vincent JL. Angus DC, et al. Among authors: mira jp. Crit Care. 2003 Jun;7(3):248-51. doi: 10.1186/cc2193. Epub 2003 May 8. Crit Care. 2003. PMID: 12793879 Free PMC article. No abstract available.
Improving clinical trials in the critically ill.
Angus DC, Mira JP, Vincent JL. Angus DC, et al. Among authors: mira jp. Crit Care Med. 2010 Feb;38(2):527-32. doi: 10.1097/CCM.0b013e3181c0259d. Crit Care Med. 2010. PMID: 19851096
Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
Bernard GR, Francois B, Mira JP, Vincent JL, Dellinger RP, Russell JA, Larosa SP, Laterre PF, Levy MM, Dankner W, Schmitt N, Lindemann J, Wittebole X. Bernard GR, et al. Among authors: mira jp. Crit Care Med. 2014 Mar;42(3):504-11. doi: 10.1097/CCM.0000000000000043. Crit Care Med. 2014. PMID: 24335445 Clinical Trial.
Sepsis: older and newer concepts.
Vincent JL, Mira JP, Antonelli M. Vincent JL, et al. Among authors: mira jp. Lancet Respir Med. 2016 Mar;4(3):237-40. doi: 10.1016/S2213-2600(15)00522-6. Epub 2016 Feb 23. Lancet Respir Med. 2016. PMID: 26917436
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial.
Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, Pettilä V, Wittebole X, Meziani F, Mercier E, Lobo SM, Barie PS, Crowther M, Esmon CT, Fareed J, Gando S, Gorelick KJ, Levi M, Mira JP, Opal SM, Parrillo J, Russell JA, Saito H, Tsuruta K, Sakai T, Fineberg D; SCARLET Trial Group. Vincent JL, et al. Among authors: mira jp. JAMA. 2019 May 28;321(20):1993-2002. doi: 10.1001/jama.2019.5358. JAMA. 2019. PMID: 31104069 Free PMC article. Clinical Trial.
Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial.
Laterre PF, Berry SM, Blemings A, Carlsen JE, François B, Graves T, Jacobsen K, Lewis RJ, Opal SM, Perner A, Pickkers P, Russell JA, Windeløv NA, Yealy DM, Asfar P, Bestle MH, Muller G, Bruel C, Brulé N, Decruyenaere J, Dive AM, Dugernier T, Krell K, Lefrant JY, Megarbane B, Mercier E, Mira JP, Quenot JP, Rasmussen BS, Thorsen-Meyer HC, Vander Laenen M, Vang ML, Vignon P, Vinatier I, Wichmann S, Wittebole X, Kjølbye AL, Angus DC; SEPSIS-ACT Investigators. Laterre PF, et al. Among authors: mira jp. JAMA. 2019 Oct 15;322(15):1476-1485. doi: 10.1001/jama.2019.14607. JAMA. 2019. PMID: 31577035 Free PMC article.
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.
François B, Wittebole X, Ferrer R, Mira JP, Dugernier T, Gibot S, Derive M, Olivier A, Cuvier V, Witte S, Pickkers P, Vandenhende F, Garaud JJ, Sánchez M, Salcedo-Magguilli M, Laterre PF. François B, et al. Among authors: mira jp. Intensive Care Med. 2020 Jul;46(7):1425-1437. doi: 10.1007/s00134-020-06109-z. Epub 2020 May 28. Intensive Care Med. 2020. PMID: 32468087 Clinical Trial.
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
François B, Lambden S, Fivez T, Gibot S, Derive M, Grouin JM, Salcedo-Magguilli M, Lemarié J, De Schryver N, Jalkanen V, Hicheur T, Garaud JJ, Cuvier V, Ferrer R, Bestle M, Pettilä V, Mira JP, Bouisse C, Mercier E, Vermassen J, Huberlant V, Vinatier I, Anguel N, Levy M, Laterre PF; ASTONISH investigators. François B, et al. Among authors: mira jp. Lancet Respir Med. 2023 Oct;11(10):894-904. doi: 10.1016/S2213-2600(23)00158-3. Epub 2023 May 31. Lancet Respir Med. 2023. PMID: 37269870 Clinical Trial.
377 results